These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 16265452

  • 1. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    McMurray JJ.
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):128-9. PubMed ID: 16265452
    [No Abstract] [Full Text] [Related]

  • 2. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
    Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN.
    Eur J Heart Fail; 2004 Dec; 6(7):937-45. PubMed ID: 15556056
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 4. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 5. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Le Jemtel TH.
    Circulation; 2000 Feb 29; 101(8):844-6. PubMed ID: 10694521
    [Abstract] [Full Text] [Related]

  • 6. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN.
    Am J Cardiol; 2002 Nov 01; 90(9):992-3. PubMed ID: 12398968
    [No Abstract] [Full Text] [Related]

  • 7. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 01; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 8. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, Val-HeFT Investigators (Valsartan Heart Failure Trial).
    J Am Coll Cardiol; 2002 Oct 16; 40(8):1414-21. PubMed ID: 12392830
    [Abstract] [Full Text] [Related]

  • 9. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 10. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN, Valsartan Heart Failure Trial Investigators.
    Circulation; 2002 Nov 05; 106(19):2454-8. PubMed ID: 12417542
    [Abstract] [Full Text] [Related]

  • 11. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG, Cerulli A, Frech FH.
    Clin Ther; 2005 Jun 05; 27(6):951-9. PubMed ID: 16117995
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 13. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 14. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec 04; 145(49):18-9. PubMed ID: 14963986
    [No Abstract] [Full Text] [Related]

  • 15. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Hollenberg NK.
    Curr Hypertens Rep; 2002 Dec 04; 4(6):411; discussion 412. PubMed ID: 12462208
    [No Abstract] [Full Text] [Related]

  • 16. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB, Schlosshan D, Williams SG.
    Int J Clin Pract; 2004 Feb 04; 58(2):184-91. PubMed ID: 15055867
    [Abstract] [Full Text] [Related]

  • 17. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
    Majani G, Giardini A, Opasich C, Glazer R, Hester A, Tognoni G, Cohn JN, Tavazzi L.
    J Card Fail; 2005 May 04; 11(4):253-9. PubMed ID: 15880333
    [Abstract] [Full Text] [Related]

  • 18. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR.
    Int J Clin Pract; 2005 May 04; 59(5):571-8. PubMed ID: 15857354
    [Abstract] [Full Text] [Related]

  • 19. [Angiotensin I receptor blockers for heart failure].
    Fruhwald FM, Kickenweiz E, Zweiker R, Klein W.
    Wien Med Wochenschr; 2001 May 04; 151(7-8):157-9. PubMed ID: 11450163
    [Abstract] [Full Text] [Related]

  • 20. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN.
    Circulation; 1999 May 25; 99(20):2658-64. PubMed ID: 10338459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.